Further research on the regulation of CTNNB1 expression by the CTNNB1 mutation-related signaling pathway is needed and will help to elucidate the new mechanism of drug resistance, providing a theoretical basis for the prediction of drug sensitivity in HCC and the development and application of new therapeutic targets for reversing drug resistance. The gene discussed is CTNNB1; the disease is hepatocellular carcinoma.